Inhibrx Biosciences, Inc.
INBX$1.16B
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaLA JOLLA156 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Oct 30, 2026
33wMarket Overview
Stock performance and key metrics
INBX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
INBRX-106
Head and Neck Squamous Cell Carcinoma (HNSCC)
INBRX-109
Conventional Chondrosarcoma
INBRX-106 - Hexavalent OX40 agonist antibody
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
INBRX-106 | Phase 3 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
INBRX-109 | Phase 2 | Conventional Chondrosarcoma | - | - |
INBRX-106 - Hexavalent OX40 agonist antibody | Phase 2 | Solid Tumor | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply